S&P 500

5.304,72

0,70%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Peregrine Pharmaceuticals Inc. (MM) (PPHMD)
Peregrine Pharmaceuticals Inc. (MM) (PPHMD) Notícias

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:PPHMD

1

Data	Hora	Fonte	Título	Código	Companhia
29/03/2019	19:42	Business Wire	Announcing VanEck Vectors ETFs’ March 2019 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
26/12/2018	21:37	Business Wire	Announcing VanEck Vectors Equity ETFs December 2018 Distribution	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
17/10/2018	12:48	Business Wire	VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
28/09/2018	19:03	Business Wire	Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
29/06/2018	19:15	Business Wire	Announcing VanEck Vectors Equity ETFs June 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
29/03/2018	18:58	Business Wire	Announcing VanEck Vectors Equity ETFs March 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
10/11/2009	12:30	PR Newswire (US)	New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
04/11/2009	17:17	PR Newswire (US)	Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
03/11/2009	18:00	PR Newswire (US)	Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements	NASDAQ:PPHMD
27/10/2009	10:17	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
23/10/2009	19:34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
21/10/2009	11:30	PR Newswire (US)	Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer	NASDAQ:PPHMD
19/10/2009	11:30	PR Newswire (US)	Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs	NASDAQ:PPHMD
19/10/2009	10:30	PR Newswire (US)	Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect	NASDAQ:PPHMD